Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biomolecules ; 14(5)2024 May 06.
Article in English | MEDLINE | ID: mdl-38785967

ABSTRACT

Mucositis is a pathological condition characterised by inflammation and ulceration of the mucous membranes lining the alimentary canal, particularly in the mouth (oral mucositis) and the gastrointestinal tract. It is a common side effect of cancer treatments, including chemotherapy and radiotherapy, and it is sometimes responsible for treatment interruptions. Preventing mucositis throughout the alimentary tract is therefore crucial. However, current interventions mainly target either oral or gastrointestinal side effects. This review aimed to investigate the use of systemically administered anti-inflammatory agents to prevent mucositis in cancer patients undergoing cancer treatment. PubMed, Ovid, Scopus, Web of Science, WHO ICTRP and ClinicalTrials.gov were screened to identify eligible randomised controlled trials (RCTs). The published literature on anti-inflammatory agents provides mixed evidence regarding the degree of efficacy in preventing/reducing the severity of mucositis in most anticancer treatments; however, sample size continued to be a significant limitation, alongside others discussed. Our review yielded a list of several anti-inflammatory agents that exhibit potential mucositis-preventive effects in cancer patients undergoing cancer treatment, which can be used to inform clinical practice.


Subject(s)
Anti-Inflammatory Agents , Chemoradiotherapy , Mucositis , Randomized Controlled Trials as Topic , Humans , Anti-Inflammatory Agents/therapeutic use , Chemoradiotherapy/adverse effects , Mucositis/prevention & control , Mucositis/chemically induced , Mucositis/etiology , Neoplasms/drug therapy , Stomatitis/prevention & control , Stomatitis/etiology , Stomatitis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...